Sernova Corp. (SEOVF)
USD 0.13
(0.15%)
USD 0.13
(0.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -40.68 Million CAD | -71.4% |
| 2022 | -24.45 Million CAD | -259.71% |
| 2021 | -6.69 Million CAD | -32.09% |
| 2020 | -4.99 Million CAD | -27.83% |
| 2019 | -3.94 Million CAD | -8.14% |
| 2018 | -3.64 Million CAD | -41.77% |
| 2017 | -2.6 Million CAD | -3.47% |
| 2016 | -2.49 Million CAD | -4.55% |
| 2015 | -2.38 Million CAD | -20.03% |
| 2014 | -2.01 Million CAD | -52.43% |
| 2013 | -1.35 Million CAD | 30.94% |
| 2012 | -1.86 Million CAD | -30.39% |
| 2011 | -1.43 Million CAD | -44.14% |
| 2010 | -992.39 Thousand CAD | -51.36% |
| 2009 | -655.66 Thousand CAD | 67.67% |
| 2008 | -2.02 Million CAD | 30.58% |
| 2007 | -2.92 Million CAD | -140.41% |
| 2006 | -1.21 Million CAD | -187.11% |
| 2005 | -423.3 Thousand CAD | 27.74% |
| 2004 | -585.81 Thousand CAD | 16.23% |
| 2003 | -699.33 Thousand CAD | 52.79% |
| 2002 | -1.48 Million CAD | 30.22% |
| 2001 | -2.12 Million CAD | -368.4% |
| 2000 | -453.21 Thousand CAD | -1382.01% |
| 1999 | -30.58 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.98 Million CAD | 13.77% |
| 2024 Q2 | -9.75 Million CAD | 2.28% |
| 2024 Q3 | -6.93 Million CAD | 28.05% |
| 2023 Q4 | -11.39 Million CAD | -16.0% |
| 2023 Q3 | -9.82 Million CAD | -5.68% |
| 2023 Q2 | -9.29 Million CAD | -15.62% |
| 2023 Q1 | -8.04 Million CAD | -1.56% |
| 2023 FY | - CAD | -71.4% |
| 2022 Q2 | -4.8 Million CAD | 10.14% |
| 2022 FY | - CAD | -259.71% |
| 2022 Q3 | -5.67 Million CAD | -18.16% |
| 2022 Q4 | -7.91 Million CAD | -39.52% |
| 2022 Q1 | -5.34 Million CAD | -126.81% |
| 2021 Q1 | -1.1 Million CAD | -22.43% |
| 2021 Q4 | -2.35 Million CAD | -51.79% |
| 2021 Q3 | -1.55 Million CAD | 2.35% |
| 2021 FY | - CAD | -32.09% |
| 2021 Q2 | -1.58 Million CAD | -44.39% |
| 2020 Q1 | -1.31 Million CAD | 24.58% |
| 2020 Q3 | -1.1 Million CAD | 34.06% |
| 2020 Q4 | -899.21 Thousand CAD | 18.52% |
| 2020 FY | - CAD | -27.83% |
| 2020 Q2 | -1.67 Million CAD | -26.89% |
| 2019 Q1 | -702.22 Thousand CAD | 13.79% |
| 2019 FY | - CAD | -8.14% |
| 2019 Q3 | -861.77 Thousand CAD | -45.02% |
| 2019 Q4 | -1.74 Million CAD | -102.95% |
| 2019 Q2 | -594.26 Thousand CAD | 15.37% |
| 2018 FY | - CAD | -41.77% |
| 2018 Q3 | -1.08 Million CAD | -12.84% |
| 2018 Q4 | -814.54 Thousand CAD | 25.26% |
| 2018 Q1 | -743.96 Thousand CAD | 23.12% |
| 2018 Q2 | -965.8 Thousand CAD | -29.82% |
| 2017 Q1 | -294.2 Thousand CAD | -62.52% |
| 2017 FY | - CAD | -3.47% |
| 2017 Q4 | -967.71 Thousand CAD | -53.29% |
| 2017 Q3 | -631.29 Thousand CAD | 3.79% |
| 2017 Q2 | -656.18 Thousand CAD | -123.04% |
| 2016 Q3 | -975.99 Thousand CAD | -51.01% |
| 2016 Q1 | -660.56 Thousand CAD | 25.18% |
| 2016 Q2 | -646.3 Thousand CAD | 2.16% |
| 2016 Q4 | -181.02 Thousand CAD | 81.45% |
| 2016 FY | - CAD | -4.55% |
| 2015 Q2 | -406.98 Thousand CAD | -0.73% |
| 2015 FY | - CAD | -20.03% |
| 2015 Q4 | -882.91 Thousand CAD | -33.22% |
| 2015 Q1 | -404.01 Thousand CAD | -3.17% |
| 2015 Q3 | -662.72 Thousand CAD | -62.84% |
| 2014 Q1 | -410.84 Thousand CAD | -34.49% |
| 2014 Q2 | -564.56 Thousand CAD | -37.42% |
| 2014 Q3 | -596.41 Thousand CAD | -5.64% |
| 2014 FY | - CAD | -52.43% |
| 2014 Q4 | -391.6 Thousand CAD | 34.34% |
| 2013 Q4 | -305.47 Thousand CAD | -51.5% |
| 2013 FY | - CAD | 30.94% |
| 2013 Q2 | -376.51 Thousand CAD | -5.74% |
| 2013 Q3 | -201.63 Thousand CAD | 46.45% |
| 2013 Q1 | -356.08 Thousand CAD | -61.01% |
| 2012 Q1 | -408.33 Thousand CAD | -49.27% |
| 2012 Q2 | -543.63 Thousand CAD | -33.13% |
| 2012 FY | - CAD | -30.39% |
| 2012 Q4 | -221.16 Thousand CAD | 47.64% |
| 2012 Q3 | -422.36 Thousand CAD | 22.31% |
| 2011 FY | - CAD | -44.14% |
| 2011 Q1 | -356.81 Thousand CAD | -31.26% |
| 2011 Q2 | -354.4 Thousand CAD | 0.68% |
| 2011 Q3 | -170.5 Thousand CAD | 51.89% |
| 2011 Q4 | -273.56 Thousand CAD | -60.45% |
| 2010 Q2 | -214.84 Thousand CAD | 10.03% |
| 2010 Q3 | -265.76 Thousand CAD | -23.7% |
| 2010 Q1 | -238.8 Thousand CAD | 13.33% |
| 2010 FY | - CAD | -51.36% |
| 2010 Q4 | -271.84 Thousand CAD | -2.29% |
| 2009 Q3 | -132.74 Thousand CAD | 23.01% |
| 2009 Q2 | -172.42 Thousand CAD | -130.08% |
| 2009 Q1 | -74.94 Thousand CAD | 75.15% |
| 2009 FY | - CAD | 67.67% |
| 2009 Q4 | -275.54 Thousand CAD | -107.58% |
| 2008 Q1 | -455.47 Thousand CAD | -92.0% |
| 2008 Q4 | -301.58 Thousand CAD | 1.78% |
| 2008 Q3 | -307.05 Thousand CAD | 66.35% |
| 2008 Q2 | -912.6 Thousand CAD | -100.36% |
| 2008 FY | - CAD | 30.58% |
| 2007 Q3 | -973.54 Thousand CAD | 5.47% |
| 2007 Q2 | -1.02 Million CAD | -208.04% |
| 2007 Q1 | -334.32 Thousand CAD | -385.64% |
| 2007 Q4 | -237.22 Thousand CAD | 75.63% |
| 2007 FY | - CAD | -140.41% |
| 2006 Q3 | -142.67 Thousand CAD | 87.39% |
| 2006 Q2 | -1.13 Million CAD | -1027.97% |
| 2006 Q1 | -100.3 Thousand CAD | -13.06% |
| 2006 Q4 | 117.04 Thousand CAD | 182.03% |
| 2006 FY | - CAD | -187.11% |
| 2005 FY | - CAD | 27.74% |
| 2005 Q3 | -76.63 Thousand CAD | 51.6% |
| 2005 Q4 | -88.71 Thousand CAD | -15.75% |
| 2005 Q1 | -79.95 Thousand CAD | 49.72% |
| 2005 Q2 | -158.34 Thousand CAD | -98.06% |
| 2004 Q4 | -159.02 Thousand CAD | -67.05% |
| 2004 Q2 | -153.73 Thousand CAD | 13.56% |
| 2004 FY | - CAD | 16.23% |
| 2004 Q3 | -95.19 Thousand CAD | 38.08% |
| 2004 Q1 | -177.86 Thousand CAD | -88.41% |
| 2003 Q3 | -82.93 Thousand CAD | 66.09% |
| 2003 FY | - CAD | 52.79% |
| 2003 Q2 | -244.59 Thousand CAD | 11.83% |
| 2003 Q1 | -277.4 Thousand CAD | -16.37% |
| 2003 Q4 | -94.4 Thousand CAD | -13.83% |
| 2002 Q2 | -463.44 Thousand CAD | -1.09% |
| 2002 Q1 | -458.44 Thousand CAD | 0.0% |
| 2002 Q4 | -238.37 Thousand CAD | 25.75% |
| 2002 FY | - CAD | 30.22% |
| 2002 Q3 | -321.03 Thousand CAD | 30.73% |
| 2001 FY | - CAD | -368.4% |
| 2000 FY | - CAD | -1382.01% |
| 1999 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -2224.862% |
| Skye Bioscience, Inc. | -13.54 Million USD | -200.313% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 143.264% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 7813.789% |
| Qrons Inc. | -40.08 Thousand USD | -101407.123% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -438.615% |
| CSL Limited | 4.78 Billion USD | 100.85% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -134.226% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -947.418% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -4242.293% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 26.48% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -10979.178% |
| Rebus Holdings, Inc. | -951 Thousand USD | -4178.136% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -6333.378% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -156.369% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 42.726% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -586.215% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -16912.365% |
| SQZ Biotechnologies Company | -64.14 Million USD | 36.569% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1438.509% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2548.683% |
| Mesoblast Limited | -62.38 Million USD | 34.789% |
| Marizyme, Inc. | -34.28 Million USD | -18.679% |
| Genus plc | 73.7 Million USD | 155.204% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -515.367% |
| Pharming Group N.V. | 9.87 Million USD | 511.917% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -2635.293% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1047.028% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -363.806% |
| ContraFect Corporation | -64.99 Million USD | 37.407% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -798.88% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2802.328% |
| IMV Inc. | -35.52 Million USD | -14.53% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1650.784% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -7753.563% |
| ONE Bio Corp. | 13.61 Million USD | 398.868% |
| Accustem Sciences Inc. | -3.74 Million USD | -985.972% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 15.638% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -3110.8% |
| Q BioMed Inc. | -617.62 Thousand USD | -6487.31% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1239.0% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1680.927% |
| Biomind Labs Inc. | -1.03 Million USD | -3832.638% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -2.645% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1306.656% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -468.126% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 605172.427% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -162640.28% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1526.127% |
| GB Sciences, Inc. | -1.41 Million USD | -2765.378% |
| Alpha Cognition Inc. | -9.7 Million USD | -319.192% |
| HST Global, Inc. | -5303.00 USD | -767108.561% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1877.884% |
| Halberd Corporation | -74.27 Thousand USD | -54673.314% |
| Enzolytics Inc. | -2.12 Million USD | -1817.272% |
| Agentix Corp. | -1.37 Million USD | -2865.912% |
| Resverlogix Corp. | -11.74 Million USD | -246.492% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1228.268% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 81.166% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 3443.062% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 559.521% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2614.318% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 10839.267% |
| AVAX Technologies, Inc. | -6.11 Million USD | -565.589% |
| Zenith Capital Corp. | -8.6 Million USD | -372.752% |
| Genscript Biotech Corporation | -248.71 Million USD | 83.642% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -233440.382% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1563.017% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -23013.318% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2018.009% |
| Kadimastem Ltd | -2.62 Million USD | -1450.273% |
| Helix BioMedix, Inc. | -1.04 Million USD | -3788.426% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -22367.016% |
| LadRx Corporation | 412.28 Thousand USD | 9968.239% |
| Cell Source, Inc. | -4.27 Million USD | -852.249% |
| Regen BioPharma, Inc. | 1.46 Million USD | 2875.327% |
| NovAccess Global Inc. | -1.03 Million USD | -3831.696% |
| Affymax, Inc. | -14.29 Million USD | -184.611% |
| Itoco Inc. | -1.86 Million USD | -2076.842% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -10617.315% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3545.616% |
| Mobile Lads Corp. | -2.24 Million USD | -1715.358% |
| CytoDyn Inc. | -18.02 Million USD | -125.665% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -51381.19% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -332593.352% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -8276.964% |
| SYBLEU INC | -141.57 Thousand USD | -28638.28% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -3730.95% |
| International Stem Cell Corporation | 202 Thousand USD | 20241.124% |
| Bioxytran, Inc. | -3.82 Million USD | -965.013% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -77189.267% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1552.567% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -13.427% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -90311.267% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1385.941% |
| Neutra Corp. | -181.24 Thousand USD | -22347.307% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -101.821% |
| PureTech Health plc | -11.62 Million USD | -249.919% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -101.835% |
| IXICO plc | -707 Thousand USD | -5654.607% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -429.409% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 15.846% |
| CSL Limited | 4.73 Billion USD | 100.86% |
| Cellectis S.A. | -92.63 Million USD | 56.081% |